secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-10-01T13:15:18+00:00
Accession:  0001437749-26-031665
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioCardia files revised De Novo pre-submission to FDA for Helix Catheter approval
--------------------------------------------------------------------------------

- Revised Pre-Submission to FDA CDRH under Q-Submission program covers the Helix Catheter for therapeutic and diagnostic agent delivery to the heart.
- In May 2026 FDA agreed there are two pathways for Helix marketing clearance and raised no concerns on safety data, device performance, or agent compatibility.
- FDA confirmed and accepted the meeting minutes in August 2026; revised submission incorporates FDA CDRH advice from those minutes.
- Helix data spans 15 clinical trials and nearly 500 patients; FDA targets acceptance/refusal review in 15 days and feedback or meeting within 70 days.
- Independent clearance could expand partnering with developers of cell, gene and protein therapeutics needing targeted heart delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926031665/0001437749-26-031665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926031665/bcda20261001_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer